Overall review of curative impact and barriers of CAR-T cells in osteosarcoma





CAR-T cell, osteosarcoma, HER2+, GD2


Osteosarcoma (OS) is a rare form of cancer and primary bone malignancy in children and adolescents. Current therapies include surgery, chemotherapy, and amputation. Therefore, a new therapeutic strategy is needed to dramatically change cancer treatment. Recently, chimeric antigen receptor T cells (CAR-T cells) have been of considerable interest as it has provided auspicious results and patients suffering from low side effects after injection that resolve with current therapy. However, there are reports that cytokine release storm (CRS) can be observed in some patients. In addition, as researchers have faced problems that limit and suppress T cells, further studies are required to resolve these problems. In addition, to maximize the therapeutic benefit of CAR-T cell therapy, researchers have suggested that combination therapy could be better used to treat cancer by overcoming any problems and reducing side effects as much as possible. This review summarizes these problems, barriers, and the results of some studies on the evaluation of CAR-T cells in patients with osteosarcoma.



How to Cite

Li, G., Wang, H., & Meftahpour, V. (2024). Overall review of curative impact and barriers of CAR-T cells in osteosarcoma. EXCLI Journal, 23, 364–383. https://doi.org/10.17179/excli2023-6760



Review articles


Most read articles by the same author(s)